10 Apr Nordion to Host Interactive TheraSphere(R) Educational Session at the SIR Annual Scientific Meeting 2013
Posted at 13:49h
in 2013
Session to complement Nordion’s educational portfolio for physicians
OTTAWA, Ontario–(BUSINESS WIRE)–Apr. 10, 2013 — Nordion Inc. (TSX: NDN) (NYSE: NDZ), a leading provider of products and services for the prevention, diagnosis and treatment of disease, will host an educational session called “TheraSphere® Test Flight Interactive: How to Treat or Should I Treat?” at the Society for Interventional Radiologists (SIR) Annual Scientific Meeting, taking place April 13-18 in New Orleans, Louisiana. The session is part of SIR’s new Industry Interactive Program, developed to provide industry partners with the opportunity to host dynamic sessions that showcase the latest Interventional Radiology technologies and research, including TheraSphere, Nordion’s Y-90 microsphere treatment for Hepatocellular Carcinoma (HCC).
“Nordion’s session will feature HCC case presentations delivered by leading physicians to challenge expert panelists in their thinking, technique, and opinion on how, or if, they would proceed with TheraSphere treatment,” said Steve West, Nordion’s Chief Executive Officer and Chief Operating Officer, Targeted Therapies. “Nordion is always looking at ways to enhance the TheraSphere learning experience, and this interactive session is a great complement to our physician educational portfolio consisting of our Centers of Excellence, proctor training and preceptor program.”
The TheraSphere® Test Flight Interactive will take place on Sunday, April 14 from 5:15-6:30 p.m. CDT, in the Ernest N. Morial Convention Center, Second Floor, Room 271. Scheduled panelists are:
-
Bulent Arslan, Director Interventional Radiology, Rush University;
- Matthew Johnson, Professor Radiology and Surgery, Indiana University; and
- Daniel Sze, Professor, Interventional Radiology, Stanford University.
Cases will be presented by physicians from hospitals acrossNorth America.
“The TheraSphere® Test Flight Interactive session will be a great forum for experienced TheraSphere users to share expertise and to assist colleagues in making informed decisions regarding the treatment of patients in different HCC scenarios,” said Dr. Sze. “Nordion’s participation in the new Industry Interactive Program demonstrates their continued commitment to work with SIR and with Interventional Radiologists to improve care for HCC patients.”
Also at the annual meeting, visit Nordion representatives at Booth #1247 to talk about TheraSphere and:
- Get a hands-on training opportunity with the TheraSphere Administration delivery system;
- Preview the upcoming Treatment Window Illustrator iPad app;
- Learn more about our Phase III trials and investigator initiated studies.
About TheraSphere®
TheraSphere is a liver cancer therapy that consists of millions of small glass beads (20 to 30 micrometers in diameter) containing radioactive Y-90. The product is injected by physicians into the artery of the patient’s liver through a catheter, which allows the treatment to be delivered directly to the tumour via blood flow.
TheraSphere is a liver cancer therapy that consists of millions of small glass beads (20 to 30 micrometers in diameter) containing radioactive Y-90. The product is injected by physicians into the artery of the patient’s liver through a catheter, which allows the treatment to be delivered directly to the tumour via blood flow.
In the US, TheraSphere is used for radiation treatment of patients with unresectable hepatocellular carcinoma (HCC) who can have appropriately positioned hepatic arterial catheters, and can be used as a bridge to surgery or transplantation in these patients. It is also indicated for the treatment of HCC patients with partial or branch portal vein thrombosis or occlusion when clinical evaluation warrants the treatment. TheraSphere is approved by the U.S. Food and Drug Administration (FDA) under a Humanitarian Device Exemption (HDE). HDE approvals are based on demonstrated safety and probable clinical benefit. However, effectiveness of the indication for use has not been established.
TheraSphere is used in the European Union and in Canada for the treatment of hepatic neoplasia in patients who have appropriately positioned arterial catheters.
Common side effects include mild to moderate fatigue, pain and nausea for about a week. Physicians describe these symptoms as similar to those of the flu. Some patients experience some loss of appetite and temporary changes in several blood tests. For details on rare or more severe side effects, please refer to the TheraSphere package insert/instructions for use at www.nordion.com/therasphere.
About Nordion Inc.
Nordion Inc. (TSX: NDN) (NYSE: NDZ) is a global health science company that provides market-leading products used for the prevention, diagnosis and treatment of disease. We are a leading provider of targeted therapies, sterilization technologies, and medical isotopes that benefit the lives of millions of people in more than 60 countries around the world. Our products are used daily by pharmaceutical and biotechnology companies, medical-device manufacturers, hospitals, clinics and research laboratories. Nordion has approximately 500 highly skilled employees worldwide. Find out more at www.nordion.com and follow us at http://twitter.com/NordionInc.
Nordion Inc. (TSX: NDN) (NYSE: NDZ) is a global health science company that provides market-leading products used for the prevention, diagnosis and treatment of disease. We are a leading provider of targeted therapies, sterilization technologies, and medical isotopes that benefit the lives of millions of people in more than 60 countries around the world. Our products are used daily by pharmaceutical and biotechnology companies, medical-device manufacturers, hospitals, clinics and research laboratories. Nordion has approximately 500 highly skilled employees worldwide. Find out more at www.nordion.com and follow us at http://twitter.com/NordionInc.
Source: Nordion Inc.
Nordion
MEDIA:
Shelley Maclean, 613-592-3400 x. 2414
Cell: 613-291-3689
[email protected]
or
INVESTORS:
Ana Raman, 613-595-4580
[email protected]
MEDIA:
Shelley Maclean, 613-592-3400 x. 2414
Cell: 613-291-3689
[email protected]
or
INVESTORS:
Ana Raman, 613-595-4580
[email protected]